NCT01939054View on ClinicalTrials.gov

Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients

PHASE2UnknownINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2016

Conditions
Breast Cancer
Interventions
DRUG

Nimotuzumab

DRUG

docetaxel

DRUG

capecitabine

Trial Locations (9)

100021

RECRUITING

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

100142

NOT_YET_RECRUITING

Beijing cancer hospital, Beijing

710032

NOT_YET_RECRUITING

Xijing Hospital, Xi’an

Unknown

NOT_YET_RECRUITING

The General Hospital of the People's Liberation Army (PLAGH), Beijing

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

NOT_YET_RECRUITING

Liaoning Cancer Hospital and Institute, Shenyang

NOT_YET_RECRUITING

FuDan University Shanghai Cancer Center, Shanghai

NOT_YET_RECRUITING

The First Affiliated Hospital of College of Medicine, Zhejiang University (First Hospital of Zhejiang Province), Hangzhou

NOT_YET_RECRUITING

Zhejiang Cancer Hospital, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Biotech Pharmaceutical Co., Ltd.

OTHER

lead

Chinese Academy of Medical Sciences

OTHER